AC Immune SA Announces Board Changes Ahead of June 2025 AGM

AC Immune SA ( (ACIU) ) has provided an announcement.

On May 19, 2025, AC Immune SA announced its upcoming Annual General Meeting (AGM) scheduled for June 19, 2025, where significant changes to its Board of Directors will be proposed. Three current board members, including Chair Dr. Douglas Williams, will not stand for re-election, with Dr. Williams transitioning to a strategic advisor role. The company plans to propose Martin Zügel as the new Board Chair and Renée Aguiar-Lucander as a new board member. These changes are part of AC Immune’s ongoing efforts to strengthen its leadership and continue its focus on precision medicine for neurodegenerative diseases, aiming to reinforce its industry position and stakeholder confidence.

The most recent analyst rating on (ACIU) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.

Spark’s Take on ACIU Stock

According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.

AC Immune SA’s stock score is constrained by its financial performance, characterized by net losses despite improving revenue and cash flow management. Technical analysis reveals a bearish trend with oversold conditions, and valuation metrics highlight profitability challenges with a negative P/E ratio. The company must improve profitability and market sentiment to drive stock performance.

To see Spark’s full report on ACIU stock, click here.

More about AC Immune SA

AC Immune SA is a Swiss-based company specializing in precision medicine for the diagnosis and treatment of neurodegenerative diseases. The company focuses on developing novel therapeutics for Alzheimer’s and Parkinson’s diseases, as well as diagnostics that enable precision medicine.

Average Trading Volume: 173,036

Technical Sentiment Signal: Sell

Current Market Cap: $169.2M

For detailed information about ACIU stock, go to TipRanks’ Stock Analysis page.